RxDoctor Payments Data

Ubaid Abbasi, MD

Family Medicine · Baton Rouge, LANPI 1548765738

Payments from drug & device makers

$718in general payments, 2019–2025

Across 33 payments — averaging $21.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$408
  • Vanda Pharmaceuticals Inc.$115
  • Novartis$63
  • Astellas Pharma US Inc$40
  • Novo Nordisk$37
  • Exact Sciences$21
  • plus $35 from 2 others

What the payments were for

  • Food & beverage$718100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$718 in reported general payments places this provider in the 50th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$89,232
Medicare patients
186
Services billed
979

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban295$107,322
OzempicSemaglutide67$71,246
MounjaroTirzepatide35$34,193
CreonLipase/Protease/Amylase33$27,688
XareltoRivaroxaban45$26,207
EntrestoSacubitril/Valsartan46$22,862
JanuviaSitagliptin Phosphate68$22,102
MyrbetriqMirabegron66$19,461
BriviactBrivaracetam14$18,270
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$16,872
LinzessLinaclotide29$16,827
Combivent RespimatIpratropium/Albuterol Sulfate26$13,674
Memantine Hcl181$13,149
RestasisCyclosporine18$10,599
TrulicityDulaglutide11$10,261

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$37$71,24667 claims
AbbVieCreon, Linzess, Restasis, Namzaric$408$62,824106 claims
NovartisEntresto$63$22,86246 claims
Astellas Pharma US IncMyrbetriq$40$19,46166 claims
AstraZenecaFarxiga$15$8,85916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →